BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Emmaus Medical, Inc. to Present at 6th Annual OneMedForum


12/20/2012 6:18:59 AM

TORRANCE, Calif., Dec. 19, 2012 /PRNewswire/ -- Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced that Peter Ludlum, the company's executive vice president and CFO, will give an overview of the company's Phase 3 sickle cell disease trial and discuss recent developments with its regenerative medicine research at the 6th Annual OneMedForum on January 8, 2013 at 9:50 a.m. P.T. at the Sir Francis Drake Hotel in San Francisco. Additionally, Yutaka Niihara, M.D., MPH, president and CEO, and Willis Lee, chief operating officer, will join Ludlum for one-on-one meetings throughout the day.

About Emmaus Medical, Inc.

Founded in 2000, Emmaus Medical, Inc. is a specialty pharmaceutical company, and subsidiary of Emmaus Life Sciences, Inc., dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases. The company is completing its Phase 3 clinical trial for a treatment for sickle cell disease and has entered into a collaborative agreement for the research, development and commercialization of regenerative medicine products. For more information, please visit www.emmausmedical.com and www.nutrestore.com.

Contacts:

Media:
IQ-PR, Inc.
Lori Teranishi
415-981-1964
lteranishi@iqprinc.com

Investors:
PondelWilkinson
Matt Sheldon
310-279-5980
msheldon@pondel.com

SOURCE Emmaus Medical, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES